Rimexolone
From Wikipedia, the free encyclopedia
|
Rimexolone
|
|
| Systematic (IUPAC) name | |
| (8S,9S,10R,11S,13S,14S,16R,17S)-11-Hydroxy-10,13,16,17-tetramethyl-17-propanoyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | H02 S01BA13 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C24H34O3 |
| Mol. mass | 370.525 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | occular |
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop solution under the trade name Vexol by Alcon Laboratories.
|
|||||||||||

